Rhode Island Medicaid does not cover Wegovy or Zepbound for weight loss

Since Oct. 1, 2026, under the state's enacted budget for fiscal year 2027, Rhode Island Medicaid no longer covers Foundayo, Saxenda, Wegovy or Zepbound when they are prescribed solely for weight loss. Continued use for a medically necessary reason other than weight loss needs a new prior authorization request.1235610

There is no prior authorization path for weight loss alone. A GLP-1 used for another medically necessary reason, or for type 2 diabetes, goes through the preferred drug list rules and prior authorization.13467

• Foundayo, Saxenda, Wegovy and Zepbound are not covered when prescribed solely for weight loss.
• Continued treatment with one of these drugs for a medically necessary indication other than weight loss needs a new prior authorization request with clinical documentation.
• Members younger than 21: every prior authorization request is reviewed for medical necessity under EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) requirements.
• Diabetes GLP-1s on the fee-for-service preferred drug list: a history of metformin or TZD therapy in the past 90 days; a non-preferred drug generally needs a trial of a preferred drug in the same class in the past 90 days.

Coverage for other uses the FDA has approved:

• Wegovy (injection), a medically necessary use other than weight loss, with a new prior authorization request: Covered with prior authorization3
• Zepbound, a medically necessary use other than weight loss, with a new prior authorization request: Covered with prior authorization3

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no EOHHS announcement that Rhode Island has joined.11

State employees' prescription drug coverage comes with every medical plan option and is administered by CVS Caremark. We found no public State of Rhode Island document that states its GLP-1 weight-loss policy.12

Pharmacy benefit: CVS Caremark (prescription drugs); Blue Cross & Blue Shield of Rhode Island (medical).

Marketplace (ACA) plans: Rhode Island's essential health benefits benchmark plan, a Blue Cross Blue Shield of Rhode Island VantageBlue small-group plan, lists prescribed weight-loss drugs among the items not covered at a pharmacy.16

On the Rhode Island Medicaid fee-for-service preferred drug list updated Oct. 1, 2026, Byetta, Ozempic, Trulicity and Victoza are preferred GLP-1s, and Mounjaro, Rybelsus, Ozempic tablets, Bydureon BCise, exenatide, liraglutide, Soliqua and Xultophy are non-preferred. The class requires a history of metformin or TZD therapy in the past 90 days, and the budget kept GLP-1 coverage for type 2 diabetes.6710

In 2025, Rhode Island Medicaid paid for 46,494 GLP-1 prescriptions, $48.8 million before rebates: 42 per 1,000 residents, against 32 across the states and DC, 13th of 51.64 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 61 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.3940303126341929

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2627281934353637383332
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.212319

In 2024, Medicare Part D drug plans paid for 67,017 GLP-1 claims from prescribers in Rhode Island, $74.8 million in total drug cost.65

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.69 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Rhode Island on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7071 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

The FDA’s register lists 0 outsourcing facilities (503B) in Rhode Island, as of November 6, 2026.66